Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 6/20 | 0.46 |
| ▸ | ABL1 | P00519 | 10/20 | 0.44 |
| ▸ | FLT3 | P36888 | 7/20 | 0.44 |
| ▸ | KIT | P10721 | 6/20 | 0.44 |
| ▸ | SIK2 | Q9H0K1 | 7/20 | 0.43 |
| ▸ | SIK3 | Q9Y2K2 | 7/20 | 0.43 |
| ▸ | SIK1 | P57059 | 6/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141953 | 0.90 | ABL1 (0.47) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14141864 | 0.89 | SRC (0.46) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14142178 | 0.88 | SRC (0.47) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14141795 | 0.88 | FLT3 (0.50) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14141851 | 0.88 | SRC (0.45) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14142048 | 0.87 | SRC (0.60) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14141994 | 0.86 | SRC (0.46) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14142537 | 0.85 | SRC (0.52) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14141782 | 0.82 | ABL1 (0.59) | SRCABL1FLT3KITSIK2 | |
| SCHEMBL14141952 | 0.80 | ABL1 (0.59) | SRCABL1FLT3KITSIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108954-B2 | Synthesis process of dasatinib and intermediate thereof | NAN JING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD. (CN) | 2015-08-18 | — | — | US | claimed |
| US-20130030177-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nan Jing Cavendish Bio-Engineering Technology Co. Ltd. (CN) | 2013-01-31 | — | — | US | claimed |
| EP-2532662-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-12-12 | — | — | EP | claimed |
| US-9108954-B2 | Synthesis process of dasatinib and intermediate thereof | NAN JING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD. (CN) | 2015-08-18 | — | — | US | disclosed |
| US-20130030177-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nan Jing Cavendish Bio-Engineering Technology Co. Ltd. (CN) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030177-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | ABL1, YES1, ABL2 | SRC 8/4885ABL1 1/4885FLT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.